Literature DB >> 16319713

Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?

Mahlon Johnson1, Steven Toms.   

Abstract

The roles of growth factor receptors and numerous downstream growth regulatory pathways are of increasing interest in neuro-oncology. These pathways have been extensively studied in gliomas but only recently analyzed in meningiomas. This article reviews current research on the growth factor receptor-Ras-Raf-1-MEK-1-MAPK, PI3K-Akt/PKB, PLC-gamma1-PKC, phospholipase A2-cyclooxygenase, and TGF-beta receptor-Smad pathways that appear to regulate meningioma growth and inhibit apoptosis. Sites along these receptor/kinase cascades that might be targeted by novel therapies are also discussed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16319713     DOI： 10.1097/01.jnen.0000189834.63951.81

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN： 0022-3069            Impact factor:   3.685


  22 in total

1.  Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

Authors:  Andrew D Norden; Jeffrey J Raizer; Lauren E Abrey; Kathleen R Lamborn; Andrew B Lassman; Susan M Chang; W K Alfred Yung; Mark R Gilbert; Howard A Fine; Minesh Mehta; Lisa M Deangelis; Timothy F Cloughesy; H Ian Robins; Kenneth Aldape; Janet Dancey; Michael D Prados; Frank Lieberman; Patrick Y Wen
Journal:  J Neurooncol       Date:  2009-06-28       Impact factor: 4.130

2.  A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.

Authors:  Jeffrey J Raizer; Sean A Grimm; Alfred Rademaker; James P Chandler; Kenji Muro; Irene Helenowski; Laurie Rice; Katie McCarthy; Sandra K Johnston; Maciej M Mrugala; Marc Chamberlain
Journal:  J Neurooncol       Date:  2014-01-22       Impact factor: 4.130

3.  Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas.

Authors:  Mahlon D Johnson; Aubie K Shaw; Mary J O'Connell; Fraser J Sim; Harold L Moses
Journal:  J Neurooncol       Date:  2010-09-19       Impact factor: 4.130

4.  Cerebrospinal fluid stimulates leptomeningeal and meningioma cell proliferation and activation of STAT3.

Authors:  Mahlon D Johnson; Mary O'Connell; Michael Facik; Paul Maurer; Babak Jahromi; Webster Pilcher
Journal:  J Neurooncol       Date:  2011-10-05       Impact factor: 4.130

Review 5.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03

6.  IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series.

Authors:  Marc C Chamberlain
Journal:  CNS Oncol       Date:  2013-05

7.  Involvement of PKC-iota in glioma proliferation.

Authors:  R Patel; H Win; S Desai; K Patel; J A Matthews; M Acevedo-Duncan
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

Review 8.  Advances in meningioma therapy.

Authors:  Andrew D Norden; Jan Drappatz; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2009-05       Impact factor: 5.081

9.  Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas.

Authors:  Mahlon D Johnson; Mary O'Connell; Fran Vito; Robert S Bakos
Journal:  J Neurooncol       Date:  2008-11-26       Impact factor: 4.130

Review 10.  Molecular targets and targeted therapies in bladder cancer management.

Authors:  Ramy F Youssef; Anirban P Mitra; Georg Bartsch; Peter A Jones; Donald G Skinner; Richard J Cote
Journal:  World J Urol       Date:  2008-11-28       Impact factor: 4.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.